Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

The levels of evidence [A-D] supporting the recommendations are defined at the end of the "Major Recommendations" field.

Basic Rules

• Hepatitis A and E can be best prevented by adequate food and drinking water hygiene, particularly in high-risk countries.
• Hepatitis B and C can be prevented by exercising due care in high risk occupations and in sexual behaviour. The single most important risk factor for hepatitis C is intravenous (IV) drug abuse.
• Prophylaxis against hepatitis A by vaccination is indicated before travelling to high-risk countries.
• Hepatitis B vaccination is indicated in high-risk occupations and for risk groups.
• (Note: Vaccination recommendations in this article are based on Finnish guidelines.)

Basic Rules of Diagnosis

• If acute viral hepatitis is suspected, the following tests should be performed: immunoglobulin M (IgM) antibodies to hepatitis A virus (anti-HAV IgM), hepatitis B surface antigen (HBsAg), IgM antibodies to hepatitis B core antigen (anti-HBc IgM), and hepatitis C virus (HCV) antibody test.
• If clinically mild hepatitis is associated with symptoms suggestive of mononucleosis (fever, lymphadenopathy, splenomegaly, upper respiratory symptoms) the following additional tests are indicated: mononucleosis rapid test or Epstein-Barr virus (EBV) antibody test and cytomegalovirus (CMV) antibody test.

Hepatitis A

Incubation Period

• 15 to 50 days

Route of Infection

• Usually faecal-oral route

Clinical Picture

• Acute onset
• Loss of appetite and nausea are the initial symptoms.
• Fever
• Jaundice

Laboratory Tests

• Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are increased.
• A specific diagnosis can be made by determining serum anti-HAV IgM.
• Total antibodies can be determined to assess the need for prophylaxis. A positive test for total antibodies (and a negative result for IgM antibodies) is indicative of an earlier infection that protects against the disease.
• See Figure 1 in the original guideline document.

Prophylaxis

• Avoidance of susceptible foods (especially mussels and other seafood) when travelling in high-risk countries
• Short-term, 80% protection may be provided by an injection of gamma globulin (suitable for short journeys lasting less than 1 or 2 months. The dose is 2 mL intramuscularly (i.m.) for adults and 0.02–0.04 mL/kg for children.
• Those who stay a long time in, or travel frequently to, high-risk countries should be vaccinated.
  • For children aged 15 or over and for adults, two doses (Havrix® 1440 ELISA-U/mL, 1 mL) of vaccine are given at months 0 and 6 to 12
  • For children aged 1 to 15 years, half the adult dose (0.5mL) is given similarly in two doses at months 0 and 6 to 12
  • The dose of Epaxal® vaccine is given the same for adults and children over 2 years of age.
• Hepatitis A+B combination vaccine
  • Given in three doses at months 0, 1, and 6
  • A separate vaccine is available for children below 16 years of age.
• Hepatitis A prophylaxis is always recommended for tourists travelling to the tropics and to the African and Middle Eastern coasts of the Mediterranean. For the Baltic countries, Russia, and former Eastern European countries, prophylaxis is recommended if the intended stay is of a long duration or repeated visits are anticipated.

Contagiousness

• One week after the onset of jaundice the virus is no longer excreted in the faeces.
• No permanent carrier status has been identified.

Course of the Disease and Follow-up

• The disease is self-limiting, and no specific treatment is available.
• Serum ALT concentrations should be monitored weekly until they start to decline.

Hepatitis B

Incubation Period

• 1 to 6 months

Route of Infection

• Parenteral (syringes used in IV drug use, blood products)
• Sexual contact
• Perinatal transmission

Clinical Picture

• Similar to that in hepatitis A, but the onset is often slower
• Joint symptoms in 10 to 20% of patients
• Skin symptoms
• Liver transaminase concentrations rise more slowly than in hepatitis A

Laboratory Diagnosis

• Increased serum ALT and AST
• A specific diagnosis is made by determining serum HBsAg and anti-HBc IgM.
• For assessment of infectiousness, the presence of hepatitis B e-antigen (HBeAg) should be determined. (If the result is positive, the patient is likely to have active hepatitis and the disease is much more infectious as the virus is actively replicating.)
• See Table 1 below and Figure 2 in the original guideline document.

1. Negative in about 10-15% of infected persons with a past history of an infection. In such cases, anti-HBc is the only marker of past infection.
2. The first test to become positive (even before clinical symptoms)
3. In the exacerbation of a chronic infection, anti-HBc-IgM may turn positive.

HBsAb -- hepatitis B surface antibody; HBc-IgG -- hepatitis B core-immunoglobulin G; HBc-IgM -- hepatitis B core-immunoglobulin M; HBeAb -- hepatitis Be antibody; HBcAg -- hepatitis B core antigen

Prophylaxis

• Avoidance of high-risk behaviour (unprotected sex with potential virus carriers, use of unclean injection needles)
• Avoidance of blood contact in occupations that involve contact with human blood

Vaccination of Risk Groups

• Target groups
  • Neonates with parents who are HBsAg positive (Andre & Zuckerman, 1994; DARE-940807, 1999) [B]. If the mother is a carrier the child should also be given, before the first vaccination, a dose of anti-hepatitis B immunoglobulin (125 IU).
  • Persons living with HBsAg carriers or with patients with an acute hepatitis B infection
  • Sexual partners of HBsAg carriers and sexual partners of patients with an acute hepatitis B infection
  • People with a bleeding disorder requiring regular treatment with blood products
  • IV drug abusers, their regular sexual partners, and others living in the same household. It is particularly important to vaccinate newborn babies of mothers who use illicit IV drugs.
  • Persons involved in prostitution
  • After needle stick injuries and blood exposure when, according to a risk assessment, prophylaxis is required and the case cannot be referred to the occupational health care
  • Health workers planning to work in endemic areas
• Vaccination against hepatitis B may also be considered in individual cases for persons who, due to their work, are at an increased risk of blood contact. Vaccination may also be considered for those under the care of such a person. For example:
  • Midwives, dental surgeons, and certain laboratory personnel
  • Staff working at a dialysis unit treating a patient who is a HBs Ag carrier. Other patients of such a unit
  • Staff at a child care centre caring for a child who is an HBsAg carrier. Other children of such a centre
  • Anyone involved in the care of IV drug abusers
• Administration of the vaccine
  • Hepatitis B vaccine 1.0 mL i.m. (0.5 mL for children)
  • The dose is repeated at 1 and 6 months. No booster injections are usually necessary after a successful initial vaccination.
  • About 10% of the vaccinated persons do not obtain sufficient immunity. If the risk of exposure to the virus is high and long-lasting, the presence of immunity should be confirmed serologically about 2 months after the third injection. If there is no antibody response, the risk of exposure should be decreased by, for example, job re-arrangements

Immune Prophylaxis After Exposure to the Virus

• Hepatitis B immunoglobulin (HepBQuin®) should be given to neonates of HBsAg positive mothers (+ HBV vaccinations) (Andre & Zuckerman, 1994; DARE-940807, 1999) [B].

Action After Exposure to Infectious Blood

• For detailed instructions, see Finnish Medical Society Duodecim guideline "Occupational Exposure to Viral Agents."

Contagiousness

• Most patients with hepatitis B infection recover; however, a small proportion (<5%) of adult patients remain carriers of the virus (in the Nordic countries).
• The determination of HBeAg is helpful in the assessment of infectivity.

Course of the Acute Disease and Follow-up

• Most cases are self-limiting.
• In the active stage of the disease serum ALT, prothrombin time and, if necessary, prealbumin and bilirubin concentrations are monitored weekly until they start to return to normal.
• HBsAg should be determined 3 months after disease onset.

Chronic Stage of the Disease

• If the HBs Ag test remains positive 6 months after the disease onset, the patient is likely to have become a hepatitis B carrier. The carrier status is confirmed by a positive HBsAg test at 12 months.
• The risk of hepatoma is increased in chronic carriers of hepatitis B.

Hepatitis C

• The most common type of hepatitis in most countries
• Most cases of non-A-non-B hepatitis after transfusion have been caused by hepatitis C. There are about 500 million carriers of hepatitis C.

Incubation Period

• 20 to 120 days

Route of Infection

• Parenteral as in hepatitis B but the infectivity is much lower. Sources of exposure include IV drug abuse, tattooing, blood transfusion, and unprotected sex with a hepatitis C positive partner. However, the chance of contracting the virus through unprotected sex is fairly low, and safe sex is not considered absolutely necessary in long-term relationships
• Hepatitis C was a common cause of transfusion hepatitis before the introduction of screening of blood products for hepatitis C virus.
• There are patients who contract hepatitis C without having ever received blood transfusions or belonging to any of the risk groups.

Clinical Picture

• The clinical presentation is usually mild. Only about 25% of infected individuals develop jaundice, compared with 50% of those infected with hepatitis B. The disease is often asymptomatic.
• Extrahepatic manifestations such as essential cryoglobulinaemia, glomerulonephritis, autoimmune thyroiditis, Sjögren's syndrome, and porphyria cutanea tarda have been reported in patients with chronic hepatitis C

Laboratory Diagnosis

• Fluctuating hepatic transaminase (ALT) concentrations are often the only manifestation of hepatitis C. The concentrations may periodically return to normal.
• Serum ALT and AST concentrations rarely exceed 800 U/L.
• A specific diagnosis is obtained by determining serum hepatitis C antibodies and by ribonucleic acid (RNA) (hepatitis c virus [HCV-]RNA)
  • Antibodies can be detected only after 4 to 6 months from exposure, and after 2 to 4 months from the onset of symptoms.
  • HCV RNA is usually positive from at symptom onset.

Contagiousness

• The majority of patients with antibodies are carriers of the virus and may spread the infection.

Course of the Disease and Follow-up

• Alcohol predisposes the patient to complications of hepatitis C
• The acute phase is often milder than in hepatitis B but the disease becomes chronic more often (in 50-80% of patients).
• Transaminase assays are not helpful in the acute phase because they tend to fluctuate. Monitoring is, however, important if specialist consultation is anticipated.
• The average times from primary infection to liver disease are: chronic hepatitis 13 years, active hepatitis 18 years, cirrhosis 21 years, and hepatoma 28 years. Some patients (20 to 30%) develop cirrhosis of the liver as soon as 5 to 7.5 years after contracting the disease.

Delta Agent (Hepatitis D)

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.